NASDAQ: TARS - Tarsus Pharmaceuticals, Inc.

Yield per half year: +99.36%
Sector: Healthcare

Company Analysis Tarsus Pharmaceuticals, Inc.

Download the report: word Word pdf PDF

1. Summary

Advantages

  • The stock's return over the last year (162.19%) is higher than the sector average (-19.51%).

Disadvantages

  • Price (47.3 $) is higher than fair price (42.17 $)
  • Dividends (0%) are below the sector average (0.5468%).
  • Current debt level 11.35% has increased over 5 years from 0%.
  • The company's current efficiency (ROE=-68.99%) is lower than the sector average (ROE=9.61%)

Similar companies

Alexion

ABIOMED

Amgen

Gilead Sciences

2. Share price and performance

2.1. Share price

2.2. News

No news yet

2.3. Market efficiency

Tarsus Pharmaceuticals, Inc. Healthcare Index
7 days 3.2% -12.7% -1.3%
90 days 52.3% -27.8% 9.3%
1 year 162.2% -19.5% 31.8%

TARS vs Sector: Tarsus Pharmaceuticals, Inc. has outperformed the "Healthcare" sector by 181.7% over the past year.

TARS vs Market: Tarsus Pharmaceuticals, Inc. has outperformed the market by 130.34% over the past year.

Stable price: TARS is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.

Long period: TARS with weekly volatility of 3.12% over the past year.

3. Summary of the report

3.1. General

P/E: 0
P/S: 33.95

3.2. Revenue

EPS -4.62
ROE -68.99%
ROA -51.04%
ROIC -25.09%
Ebitda margin -815.5%

4. Fundamental Analysis

4.1. Stock price and price forecast

The fair price is calculated taking into account the Central Bank refinancing rate and earnings per share (EPS)

Above fair price: The current price (47.3 $) is higher than the fair price (42.17 $).

Price is higher than fair: The current price (47.3 $) is 10.8% higher than the fair price.

4.2. P/E

P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (48.77).

P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (48.89).

4.2.1 P/E Similar companies

4.3. P/BV

P/BV vs Sector: The company's P/BV (3.01) is lower than that of the sector as a whole (4.82).

P/BV vs Market: The company's P/BV (3.01) is lower than that of the market as a whole (3.36).

4.3.1 P/BV Similar companies

4.4. P/S

P/S vs Sector: The company's P/S indicator (33.95) is higher than that of the sector as a whole (33.76).

P/S vs Market: The company's P/S indicator (33.95) is higher than that of the market as a whole (10.23).

4.4.1 P/S Similar companies

4.5. EV/Ebitda

EV/Ebitda vs Sector: The company's EV/Ebitda (-2.81) is higher than that of the sector as a whole (-22.15).

EV/Ebitda vs Market: The company's EV/Ebitda (-2.81) is lower than that of the market as a whole (28.27).

5. Profitability

5.1. Profitability and revenue

5.2. Earnings per share - EPS

5.3. Past profitability Net Income

Yield Trend: Rising and has grown by 523.57% over the last 5 years.

Earnings Slowdown: The last year's return (0%) is below the 5-year average return (523.57%).

Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-9.16%).

5.4. ROE

ROE vs Sector: The company's ROE (-68.99%) is lower than that of the sector as a whole (9.61%).

ROE vs Market: The company's ROE (-68.99%) is lower than that of the market as a whole (10.79%).

5.5. ROA

ROA vs Sector: The company's ROA (-51.04%) is lower than that of the sector as a whole (0.3443%).

ROA vs Market: The company's ROA (-51.04%) is lower than that of the market as a whole (6.51%).

5.6. ROIC

ROIC vs Sector: The company's ROIC (-25.09%) is lower than that of the sector as a whole (7.63%).

ROIC vs Market: The company's ROIC (-25.09%) is lower than that of the market as a whole (10.79%).

6. Finance

6.1. Assets and debt

Debt level: (11.35%) is quite low in relation to assets.

Increasing debt: over 5 years, the debt has increased from 0% to 11.35%.

Excess of debt: The debt is not covered by net income, percentage -22.24%.

6.2. Profit growth and share price

7. Dividends

7.1. Dividend yield vs Market

Low yield: The dividend yield of the company 0% is below the average for the sector '0.5468%.

7.2. Stability and increase in payments

Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.

Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.

7.3. Payout percentage

Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.

8. Insider trades

8.1. Insider trading

Insider Buying Exceeds insider sales by 100% over the last 3 months.

8.2. Latest transactions

No insider transactions have been recorded yet

Pay for your subscription

More functionality and data for company and portfolio analysis is available by subscription

9. Stocks forum Tarsus Pharmaceuticals, Inc.

9.3. Comments